Falko Fend
Falko Fend is an expert in Hematology at Universitätsklinikum Tübingen (Germany). As of October 2026, ScienceLeadR ranks Falko Fend in the top 1% of experts worldwide for Lymphoma and Lymphoproliferative Disorders. Falko Fend has authored 636 publications, the most recent in 2026, and is an investigator in 5 clinical trials, 1 of them ongoing. SLR score: 1,637 (community average: 125). How the SLR is computed.
LeadR Profile
Hematology
Subspecialties: Oncology - Immunology - Ophthalmology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1989 - 2026
Number : 636
Citations
Main journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Rare But Specific B-Cell Receptor Reactivity Against Coxsackievirus A24 in Primary Central Nervous System Lymphomas. PMID 42856814 — cells, antigens, viral, lymphoma, neoplasms, central nervous system, nervous system, b-lymphocytes, neurabins | EJHaem | 2026 | 0 |
| Genomic correlates of metastatic competence and progression in human melanoma. PMID 42856273 — genes, melanoma, point mutation, neoplasm metastasis, clone cells, chromosomal instability, mutation | bioRxiv | 2026 | 0 |
| CD4+ T cells orchestrate the immune response to ALK-positive T-cell lymphoma. PMID 42520200 — cells, hematology, lymphoma, immunotherapy, immunity, t-lymphocytes, lymphoma, t-cell | Blood | 2026 | 0 |
| Molekulare Pathologie als Innovationstreiber und Garant einer optimierten onkologischen Versorgung. PMID 42360475 — pathology, pathologic processes | Pathologie (Heidelb) | 2026 | 0 |
| Evaluation of Prognostic Factors and Outcomes in Primary versus Secondary Myeloid Sarcoma. PMID 42320544 — cells, neoplasms, pathology, multiple chronic conditions, sarcoma, myeloid, sarcoma, cytogenetics, mutation, prognosis | Hum Pathol | 2026 | 0 |
Clinical Studies 5
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
Ongoing trial started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| PAX5 NEGATIVE HODGKIN LIKE LYMPHOMAS A DIAGNOSTIC CHALLANGE NCT07313943 — cells, absenteeism, lymphocytes, hodgkin disease, lymphoma, neoplasms, diagnosis, lymphoma, non-hodgkin, t-lymphocytes, b-lymphocytes | N/A | Recruiting | 2025 |
LeadR Networks
Main global connection map